Navigation Links
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Date:8/11/2009

SEATTLE, Aug. 11 /PRNewswire/ -- Omeros Corporation today announced results from the Phase 1/Phase 2 clinical trial of OMS302, the Company's ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles.

Omeros' Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of Omeros' product candidate added to a standard surgical irrigation solution. The data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control. There were no serious adverse events and no discontinuations due to adverse events.

This Phase 1/Phase 2 clinical trial was a parallel-group, double-blind, vehicle-controlled study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. The trial included three arms of equal size. In the first arm, OMS302 including both the mydriatic and anti-inflammatory agents was added to a standard irrigation solution used in ophthalmologic surgery and delivered directly to the eye during the operation. In the second arm, patients received irrigation solution including only the mydriatic agent, and in the third arm, patients received standard irrigation solution only. For efficacy assessments, patients were monitored for pupil size during surgery and for pain and inflammation for 14 days following surgery.

"We are pleased with the results of this study, which suggest that OMS302 would be useful in helping maintain mydriasis throughout cataract surgery a
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Pfanstiehl has announced the launch of ... the USA under ICH ... for playing a key role in protein glycosylation.  ... that media supplementation with mannose can improve overall ... to Dr. Christopher Wilcox , VP, Business ...
(Date:10/1/2014)... CA (PRWEB) September 30, 2014 ... user-friendly, cost-effective tools to address sales, training and ... has developed innovative mobile applications to turn ... outlining the agency’s latest customized mobile app creations, ... http://www.studiopmg.com/work . , In partnership with Toyota, StudioPMG ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... available in German . ... quantum dots in a semiconductor layer. Quantum dots are small ... processes. If a short laser pulse is fired at the ... dot experiences a change in the electromagnetic field around it. ... of light by the dot. As soon as the refractive ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2
... Inc. (Nasdaq: VRUS ), a clinical ... commercializing novel drugs to treat viral infections, reported ... quarter ended December 31, 2008. Financial Results ... quarters ended December 31, 2008 and December 31, ...
... Vitro Technologies (Celsis,IVT), a division of Celsis International ... company, and Wisconsin-based Promega Corp,will take the trial ... Celsis IVT is pre-qualifying lots of its ... assays, including,the P450-Glo(TM) CYP Assay used to study ...
... the Clinical and Economic Value of Pharmaceuticals in ... ExL Pharma today announced the start of the ... Marketing for the Pharmaceutical Industry at the Loews ... markets marketers with strategic insights needed to prepare ...
Cached Biology Technology:Pharmasset Reports Fiscal First Quarter 2009 Financial Results 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 4Pharmasset Reports Fiscal First Quarter 2009 Financial Results 5Pharmasset Reports Fiscal First Quarter 2009 Financial Results 6Pharmasset Reports Fiscal First Quarter 2009 Financial Results 7Pharmasset Reports Fiscal First Quarter 2009 Financial Results 8Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 3
(Date:9/30/2014)... have completed the first comprehensive numerical simulation of skeletal ... in an image as data points for the computer ... led by J.S. Chen, the William Prager Professor of ... UC San Diego, presented their findings on the development ... this month. Chen also gave a keynote speech about ...
(Date:9/30/2014)... D.C., September 30, 2014--Sea monkeys have captured the popular ... their easily observable life cycle -- sold as dehydrated ... mate given little more than a tank of salt ... shorter-term pattern: Like other zooplankton, brine shrimp vertically migrate ... coming closer to the surface at night and retreating ...
(Date:9/30/2014)... tetrachloroethylene (PCE) in drinking water may increase the ... a new study led by a Boston University ... published in the journal Environmental Health , ... among 1,766 women in Cape Cod, Ma., where ... the early 1980s by the installation of vinyl-lined ...
Breaking Biology News(10 mins):First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Contaminated water linked to pregnancy complications, BU study finds 2
... unique aroma signature of the durian revered as the ... the world,s foulest smelling food has uncovered several new ... ACS, Journal of Agricultural and Food Chemistry . ... food shops in the United States and elsewhere, has a ...
... in a Duke University-led study contained potentially toxic or untested chemical ... Among the chemicals detected was "Tris," a chlorinated flame ... studies. "Tris was phased out from use in ... it still showed up in 41 percent of the couch foam ...
... Toronto, ON (27 November, 2012) -- A new method of ... The discovery, which transforms aged stem cells into cells that ... to grow cardiac patches for damaged or diseased hearts from ... avoiding the threat of rejection. Stem cell therapies ...
Cached Biology News:Potentially toxic flame retardants found in many US couches 2'Fountain of youth' technique rejuvenates aging stem cells 2
... media and other fluid sources for 8 ... speed of each individual pump is controlled ... are exactly maintained. ,High-precision controlled miniature ... types, which allows flow rates between 0 ...
The Mu-End™ Protein Truncation Kit provides a convenient method for generating a library of N-terminal and C-terminal protein deletions that can be expressed in E. coli....
... cassette is designed to allow ampicillin ... promoter gb2 driving the gene for ampicillin ... the Em7 promoter. It mediates higher transcription ... A synthetic polyadenylation signal terminates the ampicillin ...
... PRO S-7 stirrers deliver accurate ... channels fluids away from internal ... easy-to-use controls which allow users ... ceramic tops feature a chemical ...
Biology Products: